|
Substance active |
Arsenic trioxide |
|
Holder |
Teva Pharma Belgium |
|
Status |
Closed |
|
Indication |
In combination with alltrans retinoic acid (ATRA) for the first‐line treatment of low or intermediate risk acute promyelocytic leukemia (APL) |
|
Public documents |
|
|
Last update |
04/04/2018 |
Trisenox®
Last updated on 23/04/2024